Video: Interview With Baiju Shah Of BioMotiv
In an interview at the recent BioPharm America conference, Shah explains the role that BioMotiv, a self-described accelerator, plays in advancing academic research into private-sector biopharma companies.
You may also be interested in...
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
Formerly an executive with Genzyme and TetraLogic, Sarah Frew of the University of Pennsylvania's Center for Innovation spoke with "The Pink Sheet" at BioPharm America about the deal-making atmosphere between academia and private industry.
The former Teva CEO now heads up neuroscience-focused Ovid. At BioPharm America, he discussed the trend of execs moving from large pharmas to smaller companies as well as the business strategy for Ovid.